Clinical study shows Matrikynes significantly improves the structure, function, and appearance of skin

Clinical Trials & Research

NEW YORK, April 5, 2023. Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent clinical study that validated that their proprietary Matrikynes ingredient is safe and highly effective for anti-aging and other topical skin applications.

Developed through biomedical research aimed at better understanding and promoting tissue repair and wound healing, Matrikynes is comprised of a proprietary mixture of natural extracellular matrix-derived peptides called matrikines. The intrinsic bioactivity of matrikines has been shown to activate regenerative mechanisms that can drive tissue repair and reverse the effects of aging.

The independent study evaluated the clinical safety and efficacy of Matrikynes for topical skin applications in 56 female volunteers, age 35 to 65, representing different skin types and tones. Standard dermatological assessments were performed using clinical instrumentation and validated measurement techniques. Topical application of Matrikynes showed a robust clinical safety profile and multiple statistically significant improvements in the structure, function, and appearance of damaged and aging skin.


  • Safety testing showed no allergic sensitization or irritant reaction to Matrikynes
  • Topical application of Matrikynes significantly improved skin barrier repair
  • Topical application of Matrikynes; increased skin density and decreased the appearance of global fines lines and deep wrinkles

Dr. John O’Neill, Chief Scientific Officer of Xylyx Bio, stated, “As a pioneer in regenerative medicine, Xylyx Bio developed Matrikynes in response to the increasing demand in topical skincare for evidence-based ingredients that can effectively address skin damage and aging. This study confirms that Matrikynes is safe and offers multiple functional and cosmetic benefits. Such significant reparative capabilities in a single ingredient pave the way for a new paradigm of regenerative skincare.”

About Xylyx Bio
Xylyx Bio is a regenerative medicine company focused on discovering and developing innovative approaches for tissue repair and regeneration. .

SOURCE Xylyx Bio, Inc.

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Articles You May Like

FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira
RECOVER study: An important step toward defining long COVID
‘Medically Relevant to Saving the Life of Your Patient’: What We Heard This Week
Illumina shareholders oust board chair, CEO survives Carl Icahn proxy battle
Takeda and Hutchmed Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Leave a Reply

Your email address will not be published. Required fields are marked *